logo.png
ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp
March 04, 2021 08:32 ET | Arch Biopartners
TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that one of its lead scientists, Dr. Daniel Hassett,...
Retrophin Logo.jpg
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
September 21, 2020 08:00 ET | Retrophin, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
June 16, 2019 12:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 01, 2019 08:00 ET | VBI Vaccines, Inc.
All four lead pipeline programs progressing towards expected clinical milestones in 2019Gearing up for top-line data from the pivotal Phase 3 study of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine,...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call
April 23, 2019 08:00 ET | VBI Vaccines, Inc.
10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBMExpanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
October 16, 2018 08:00 ET | VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
biometric credit card
SmartMetric And Protec Secure Card Have Entered Into An Agreement Appointing Protec Secure Card As SmartMetric's Representative And National Distributor For The Fingerprint Activated Biometric Credit And Security Card
December 26, 2017 15:20 ET | SmartMetric Inc
NEW YORK, Dec. 26, 2017 (GLOBE NEWSWIRE) -- SmartMetric, Inc. (OTCQB:SMME) – SmartMetric, the developer of the biometric credit card and Cyber/Access/Identity multi-function security card, is...
DynaTrap Celebrates National Mosquito Awareness Week with Simple Yet Effective Mosquito Prevention Insights
June 26, 2017 13:52 ET | Dynamic Solutions Worldwide, LLC
MILWAUKEE, June 26, 2017 (GLOBE NEWSWIRE) -- DynaTrap® (www.dynatrap.com) is the creator of technology-driven, indoor/outdoor insect and mosquito traps that are chemical, pesticide, and hassle free....
Informatica Advances
Informatica Advances Data Security Intelligence with Detection and Protection of Security Threats
March 01, 2017 10:00 ET | Informatica
Redwood City, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Next generation data security challenges require next generation solutions. Informatica®, the world’s No. 1 provider of data management...
Mission Ready Acquires ForceOne Armor Business
September 22, 2016 10:54 ET | Mission Ready Services Inc.
VANCOUVER, BC--(Marketwired - September 22, 2016) - Mission Ready Services Inc. ("Mission Ready" or the "Company") (TSX VENTURE: MRS) is pleased to announce that PTF Manufacturing Inc. ("PTFM") has...